American Journal of Epidemiology Advance Access published online on August 30, 2006
American Journal of Epidemiology, doi:10.1093/aje/kwj289
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Pharmacy Administration, College of Pharmacy, University of Illinois at Chicago, Chicago, IL; Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, IL
* To whom correspondence should be addressed. To evaluate risk of new-onset type 2 diabetes associated with use of selected antipsychotic agents, the authors conducted a new-user cohort study in a national sample of US Veterans Health Administration patients with schizophrenia (and no preexisting diabetes). The authors studied 15,767 patients who initiated use of olanzapine, risperidone, quetiapine, or haloperidol in 1999-2001 after at least 3 months with no antipsychotic prescriptions. Patients were followed for just over 1 year. New-onset diabetes was identified through diagnostic codes and prescriptions for diabetes medication. In Cox proportional hazards regression adjusting for potential confounders, with patients initiating haloperidol use designated the reference group, diabetes risk was increased equally with new use of olanzapine (hazard ratio (HR) = 1.64, 95% confidence interval (CI): 1.22, 2.19), risperidone (HR = 1.60, 95% CI: 1.19, 2.14), or quetiapine (HR = 1.67, 95% CI: 1.01, 2.76). Diabetes risks were higher in patients under age 50 years. When data were reanalyzed with prevalent-user cohorts and matched case-control designs, results were similar, with slightly less elevated risk estimates. Assuming that the observed associations are causal, approximately one third of new cases of diabetes may be attributed to use of olanzapine, risperidone, and quetiapine in patients taking these medications. Prescribers should be mindful of diabetes risks when treating patients with schizophrenia.
Received August 22, 2005
Accepted March 2, 2006
ORIGINAL CONTRIBUTIONS
Diabetes Risk Associated with Use of Olanzapine, Quetiapine, and Risperidone in Veterans Health Administration Patients with Schizophrenia
Bruce L. Lambert 1 *, Francesca E. Cunningham 2, Donald R. Miller 3, Gregory W. Dalack 4, and Kwan Hur 5
2 Department of Veterans Affairs, Pharmacy Benefits Management Strategic Healthcare Group, Hines, IL
3 Center for Health Quality, Outcomes, and Economic Research, Veterans Health Administration, Bedford, MA; Department of Health Services, School of Public Health, Boston University, Boston, MA
4 Psychiatry Service, VA Ann Arbor Healthcare System, Ann Arbor, MI; Department of Psychiatry, Medical School, University of Michigan, Ann Arbor, MI
5 Cooperative Studies Program Coordinating Center, Edward Hines, Jr. VA Hospital, Hines, IL; Center for Health Statistics, Department of Psychiatry, College of Medicine, University of Illinois at Chicago, Chicago, IL
Bruce L. Lambert, E-mail: lambertb{at}uic.edu
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. P. Kruszewski and R. P. Paczynski Antipsychotic Agents and Cardiometabolic Morbidity in Youth Arch Pediatr Adolesc Med, April 1, 2009; 163(4): 394 - 395. [Full Text] [PDF]
|
|
|
|
 |
|
 D. W. Haupt, L. C. Rosenblatt, E. Kim, R. A. Baker, R. Whitehead, and J. W. Newcomer Prevalence and Predictors of Lipid and Glucose Monitoring in Commercially Insured Patients Treated With Second-Generation Antipsychotic Agents Am J Psychiatry, March 1, 2009; 166(3): 345 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Leucht, K. Komossa, C. Rummel-Kluge, C. Corves, H. Hunger, F. Schmid, C. Asenjo Lobos, S. Schwarz, and J. M. Davis A Meta-Analysis of Head-to-Head Comparisons of Second-Generation Antipsychotics in the Treatment of Schizophrenia Am J Psychiatry, February 1, 2009; 166(2): 152 - 163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hammerman, J. Dreiher, S. H Klang, H. Munitz, A. D Cohen, and M. Goldfracht Antipsychotics and Diabetes: An Age-Related Association Ann. Pharmacother., September 1, 2008; 42(9): 1316 - 1322. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Smith, D. Hopkins, R. C. Peveler, R. I. G. Holt, M. Woodward, and K. Ismail First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis The British Journal of Psychiatry, June 1, 2008; 192(6): 406 - 411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L Dufresne Weighing In: Emergent Diabetes Mellitus and Second-Generation Antipsychotics Ann. Pharmacother., October 1, 2007; 41(10): 1725 - 1727. [Abstract] [Full Text] [PDF]
|
|